|
| Study ID | Participants (M/F) | Age (years) | Intervention | Underlying disease | Medicine used for underlying disease | Control | Duration of treatment (I/C) | Time point of assessment | Outcomes |
|
| Casault et al. [23] | I: 1/19
C: 2/16 | I: 56.9 ± 10.8
C: 57.0 ± 9.4 | CBT-I (self-administered) weekly | Nonmetastatic cancer | None | No treatment | 6 weeks/6 weeks | Week 6 | ISI, HADS-D |
| Daniel et al. [24] | I: 62/13
C: 62/14 | I: 32.21 ± 7.18
C: 32.67 ± 7.97 | CBT-I, weekly | None | None | No treatment | 6 weeks/6 weeks | Week 6 | ISI, BDI |
| Shan [25] | I: 26/18
C: 24/20 | I: 54.22 ± 8.39
C: 54.23 ± 8.42 | CBT-I, weekly | Ischemic stroke | Aspirin; simvastatin | No treatment | 4 weeks/4 weeks | Week 4 | PSQI,SDS |
| Wang et al. [26] | I: 18/25
C: 18/27 | I: 57.19 ± 8.51
C: 56.73 ± 8.96 | CBT-I, weekly | Various types of cancer | Chemotherapy drugs | No treatment | 4 weeks/4 weeks | Week 4 | PSQI,SDS |
| Hou et al. [27] | I: 20/31
C: 22/25 | I: 54.5 ± 13.8
C: 52.4 ± 14.5 | CBT-I, weekly | Maintain hemodialysis (MHD) | None | No treatment | 12 weeks/12 weeks | Week 12 | PSQI, SCL-90 |
| Yang et al. [28] | I: 20/30
C: 19/34 | I: 56.54 ± 9.97
C: 56.73 ± 11.27 | CBT-I (remote-interactive), more than once a week | Hypertension | Antihypertensive drugs | No treatment | 8 weeks/8 weeks | Week 8 | ISI,PSQI, BDI |
| Sylvia et al. [29] | I: 6/3
C: 5/1 | I: 47.22 ± 15.21
C: 51.17 ± 10.65 | CBT-I (individual), weekly | Poststroke fatigue | Medicine (specific drugs not available) | No treatment (waitlist control) | 8 weeks/8 weeks | Week 8 | ISI,PSQI,HADS-D |
| Markus et al. [30] | I: 7/10
C: 5/10 | I: 57.8 ± 6.6
C: 53.6 ± 10.4 | CBT-I, weekly | Hearing impairment | Not mentioned | No treatment (waitlist control) | 7 weeks/7 weeks | Week 8 | ISI, HADS-D |
| David et al. [31] | I: 20/82
C: 20/82 | I: 44.66 ± 11.65
C: 43.75 ± 11.84 | CBT-I (web-based), weekly | None | None | No treatment (waitlist control) | 6 weeks/6 weeks | Week 7 | ISI,QIDS-CR16 |
| Lancee et al. [32] | I: 6/30
C: 7/20 | I: 47.47 ± 14.37
C: 49.98 ± 13.71 | CBT-I (online), weekly | None | None | No treatment (waitlist control) | 12 weeks/12 weeks | Week 12 | ISI, CES-D, adverse event |
| (1) Lancee et al. [33] | I: 4/26
C: 5/25 | I: 41.2 ± 14.1
C: 45.1 ± 13.7 | CBT-I (online), weekly | None | None | No treatment (waitlist control) | 12 weeks/12 weeks | Week 12 | ISI, CES-D |
| (2) Lancee et al. [33] | I: 8/22
C: 5/25 | I: 38.5 ± 13.1
C: 45.1 ± 13.7 | CBT-I (individual, face to face), weekly | None | None | No treatment (waitlist control) | 12 weeks/12 weeks | Week 12 | ISI, CES-D |
| Lorenz et al. [34] | I: 8/21
C: 9/18 | I: 41.72 ± 17.31
C: 44.04 ± 20.05 | CBT-I (web-based), weekly | None | None | No treatment (waitlist control) | 6 weeks/6 weeks | Week 6 | ISI,BDI |
| Talbot et al.[35] | I: 7/22
C :7/9 | I: 37.1 ± 10.4
C: 37.3 ± 11.0 | CBT-I (individual), weekly | Posttraumatic stress disorder (PTSD) | Medicine (specific drugs not available) | No treatment (waitlist control) | 8 weeks/8 weeks | Week 8 | ISI,BDI |
| Han and Liu [36] | I: 14/17
C: 14/18 | I: 37 ± 14
C: 35 ± 14 | CBT-I, weekly | None | None | Zopiclone 3.75～11.25 mg QN | 8 weeks/8 weeks | Week 8 | PSQI,SCL-90 |
| Huang et al. [37] | I: 35/93
C: 28/85 | I: 46.78 ± 13.75
C: 45.49 ± 12.83 | CBT-I (group), weekly | None | None | Zopiclone 3.75～7.5 mg QN | 8 weeks/8 weeks | Week 8 | ISI,HAMD |
| Zhou et al. [38] | 150/160 | None | CBT-I, weekly | None | None | Estazolam 1 mg QN | 6 weeks/6 weeks | Week 6 | PSQI,SDS |
| Lin et al. [39] | I: 4/16
C: 4/17 | I: 46.5 ± 12.5
C: 45.5 ± 12.4 | CBT-I (remote-interactive), weekly | None | None | Benzodiazepine agonist | 8 weeks/8 weeks | Week 8 | ISI,PSQI, HAMD |
|
